JP2005053930A5 - - Google Patents

Info

Publication number

JP2005053930A5

JP2005053930A5 JP2004325133A JP2004325133A JP2005053930A5 JP 2005053930 A5 JP2005053930 A5 JP 2005053930A5 JP 2004325133 A JP2004325133 A JP 2004325133A JP 2004325133 A JP2004325133 A JP 2004325133A JP 2005053930 A5 JP2005053930 A5 JP 2005053930A5

Authority

JP

Japan

Prior art keywords

gly

asp

seq

pro

glu

Prior art date

2004-11-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001413 amino acids Chemical group 0.000 claims description 30
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
• 108090000190 Thrombin Proteins 0.000 claims description 19
• 229960004072 thrombin Drugs 0.000 claims description 19
• 239000012634 fragment Substances 0.000 claims description 11
• 238000006467 substitution reaction Methods 0.000 claims description 5
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 238000000034 method Methods 0.000 description 17
• 210000000845 cartilage Anatomy 0.000 description 10
• 108020002447 serine esterase Proteins 0.000 description 7
• 102000005428 serine esterase Human genes 0.000 description 7
• 108091036078 conserved sequence Proteins 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 210000001612 chondrocyte Anatomy 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• HZKLCOYAVAAQRD-VGMNWLOBSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxyethyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N HZKLCOYAVAAQRD-VGMNWLOBSA-N 0.000 description 2
• 206010007710 Cartilage injury Diseases 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 108010086780 arginyl-glycyl-aspartyl-alanine Proteins 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 210000001503 joint Anatomy 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000008736 traumatic injury Effects 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 description 1